Cure My Disease

Don't miss your cure!

 Log in / Sign up

New oral drug shows promise for ulcerative colitis in early trial

NCT ID NCT05291689

Completed Disease control Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental pill called MORF-057 in 39 adults with moderate to severe ulcerative colitis. The drug aims to reduce gut inflammation by blocking a specific protein. Researchers measured changes in colon tissue health and symptom scores after 12 weeks of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MORF-057 (an oral pill that blocks a protein involved in gut inflammation)
What this could lead to
If it works, this could point toward a new daily pill to control ulcerative colitis symptoms and reduce gut damage.
What could go wrong
This is a small, early-phase trial with only 39 people and no placebo group, so results may not hold up in larger studies. The drug may cause side effects or not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLITIS, ULCERATIVE INFLAMMATORY BOWEL DISEASES

Contacts and locations

Locations

  • Clinical Study Site

    Tampa, Florida, 33609, United States

  • Clinical Study Site

    Lafayette, Louisiana, 70503, United States

  • Clinical Study Site

    Freehold, New Jersey, 07728, United States

  • Clinical Study Site

    Brooklyn, New York, 11235, United States

  • Clinical Study Site

    New York, New York, 10075, United States

  • Clinical Study Site

    Bydgoszcz, 85-794, Poland

  • Clinical Study Site

    Elblag, 82-300, Poland

  • Clinical Study Site

    Katowice, 40-748, Poland

  • Clinical Study Site

    Lodz, 90-349, Poland

  • Clinical Study Site

    Lodz, 90-752, Poland

  • Clinical Study Site

    Oświęcim, 32-600, Poland

  • Clinical Study Site

    Sopot, 81-756, Poland

  • Clinical Study Site

    Sosnowiec, 41-209, Poland

  • Clinical Study Site

    Staszów, 28-200, Poland

  • Clinical Study Site

    Tychy, 43-100, Poland

  • Clinical Study Site

    Warsaw, 00-728, Poland

  • Clinical Study Site

    Warsaw, 02-665, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.